25th May 2022

Life Science Webinar















10.00-10.20	Welcome and presentation of the European standardization strategy 2025 Jeanett Fleron, Senior Consultant and Maibritt Agger, Head of department Danish Standards
10.20-10.40	Why is standardization important for business and the life science industry? Michael Bremerskov Jensen, Functional Manager International Trade, Danish Chamber of Commerce
10.40-10.55	Questions and debate
10.55-11.15	The importance of standardization for future use of diagnostics and personalized medicine Ulf Bech Christensen, Founder and CEO, PentaBase
11.15-11.20	Short break
11.20-11.40	Standardization and innovation are prerequisites for each other Martin Vesterby, MD Ph.d. of Health Tech Adopter Partner, Health Tech Hub Cph.
11.40-12.00	From research to practice to standardization Serkawt Khola, Ph.d., CEO & Founder EvoPlexus Medics, member of S-273 Health informatics and ISO/TC 215 Health informatics
12.00-12.20	Why innovation and investment in evidence-based standards are crucial for trade in the future Gitte Petersen, CEO & co-founder, Genomic Expression (online from USA)
12.20-12.50	Panel debate and questions By all presenters and the chair of the DS committee, Health informatics, Frederik Endsleff, Elisabeth Erhardtsen, (DVM, mBA), Senior RA Specialist, Regulatory Affairs Solutions i KLIFO A/S, representing Dansk Biotek
12.50-13.00	Conclusion and next steps Jeanett Fleron, Senior Consultant, Danish Standards.



Welcome and presentation of the European standardization strategy 2025

Jeanett Fleron, Senior Consultant and Maibritt Agger, Head of department Danish Standards



What is Danish Standards?

- Denmark's official standardization organization
- Commercial foundation, founded in 1926
- 182 employees
- Corporate partnership with the Danish Ministry of Business Affairs

We are a member of:











A strong platform of solid brands:













Basic premises of Danish Standards

1. Danish Standards operates for the benefit of society

Non-profit commercial foundation, co-financed by performance contracts.

2. Danish Standards is Denmark's representative in the international organizations

- International Organization for Standardization (ISO/IEC)
- European Committee for Standardization (CEN/CENELEC)
- European Telecommunications Standards Institute (ETSI)
- Nordic and European ecolabels.

3. Danish Standards is market-driven

Many services are provided on regular commercial terms, with focus on customers' needs.





Vision Danish Standards wants to be a driving force of sustainable development

Ambition Our ambition is to contribute to a sustainable and safe society and business community for people, the environment and the market

Strategic action areas



People

Strategic themes

A safe society

Confidence, safety and security for all

Strategic action areas

Sustainability

Safety for citizens

- Safe products
- Digital trust
- Healthy and diverse workplaces



Environment

A green future

Climate and environmental improvements globally

Green circular transition

- Circular economy in construction
- Transition of the energy system
- Green digitization
- · Greener procurement
- Environmental improvement tools



A strong business community

Sustainability as a competitive advantage

Resilient enterprises

 Sustainable, digital and resilient enterprises

Partnerships









Danish Standards – a strong player in a European and global standardisation network

Everyone can make an impact:

Industries, authorities, NGOs, research and education provide input to the work of Danish Standards and participate in our standardization committees.





Geopolitics of standardization

Highlights from the EU Standardization Strategy





- More assertiveness by trading partners, pursue geopolitical ambitions at EU/international level (cf. Chinese standardization strategy)
- Increased complexity and need for resources
- Not only about technicalities, also about democratic values



Good Governance

- Systems will have to deliver on implementation key in EU policies – incl. an human approach to AI, cyberresilience, defense, green technologies – and requirements to EU guidance
- Cybersecurity and tele communication



Priority setting and speed


- We need to steer the system better to deliver on our priorities; Today scattered activities and industry-driven
- Systems are not plugged into the research and innovators community, no anticipation and prioritization or sense of urgency
- Risk for Twin transition and resilience



Legislation on the strategies related to standardization in the healthcare area

Strategies:

- EU European
 Standardization Strategy
- CEN & CENELEC's Advisory
 Board for Healthcare
 Standards' strategy: Mobile
 applications, Cybersecurity,
 AI, Biotechnologies and
 others new technologies



Legislation and soft law:


- European Data Health Space (EDHS) a proposal for the new legislation has just been published
- MDCG Guidance (Medical Devices Coordination Group)
- IMDRF (International Medical Devices Regulators Forum)



Harmonized standards will manage the market of the future...!




If you are not around the table – You will find yourself at the menu...!





Biotechnology



WG 1: Terms and definitions: working for harmonized standards for biomarker, biomaterial, biological material, cell, personalized medicine, regenerative medicine, medicine, synthetic biology

WG 2: Biobanks and bioresources

WG 3: Analytical methods, including personalized medicine & diagnostic


WG 4: Bioprocessing

WG 5: Data processing including annotation, analysis, validation, comparability and integration

WG 6: Metrology.







SC 1: Genomic Informatics

AGH 4: Standards and conformance

AGH 5: Safe, effective & Secure Digital Terapeutics

AGH 6: Content of risk and associated terms

CAG 1: Execitice council, harmonization & operations

CAG 2: Advisory group

JWG 1: Traditional Chinese Medicine (Informatics – TC 249)

JWG 7: Safe, effective & secure health software and health IT systems,

including those incorporation medical devices (IEC 62A)

TF 1: Task Force on Quantities and Units to be used in e-health

TF 5: Al technologgies in health informatics

WG 1: Architecture, Framework and Models

WG 2: Systems and Device interoperability

WG 3: Semantic content

WG 4: Security, Safety & privacy

WG 6: Pharmacy and medicine business

WG 10: Traditional medicine

WG 11: Personalized digital health



Action point 1



Anticipate, prioritize and address standardization needs in strategic areas

- We need standards faster and in tune with the European innovation and policy agenda.
- The Commission has identified standardization urgencies as regards COVID-19 vaccine and medicine production, chips certification and data standards.
- As of this year, standardization priorities will be clearly identified in the 2022 annual Union Work Programme for European standardization.
- A High-level Forum will be set up to inform future standardization priorities.
- The Commission will establish the function of a Chief Standardization Officer to ensure high-level guidance across the Commission on standardization activities, which will be supported by an EU excellence hub on standards composed of Commission services.







Improve the governance and integrity of the European standardization system

- European standards, which support EU policy and legislation, must be
 decided by European players. The Commission is proposing an
 amendment to the <u>Regulation on standardization</u> to improve the
 governance in the European standardization system.
- The Commission will further pay close attention to the inclusiveness of the system, and the role of SMEs and civil society. At the same time, the Commission will launch the evaluation of the Regulation on standardization.



Action point 3



Enhance European leadership in global standards

- The Commission will work through the High-Level Forum to set up a new mechanism with EU Member States and national standardization bodies to share information, coordinate and strengthen the European approach to **international standardization**.
- The Commission will also pursue more coordination between EU
 Member States and like-minded partners. The EU will fund
 standardization projects in African and the Neighbourhood countries.



Action point 4



Support innovation

- The Commission is proposing to better tap into the potential of EU-funded research to valorise **innovation projects** through standardization activities and **anticipate early standardization needs**.
- A 'standardization booster' to support researchers under Horizon 2020 and Horizon Europe to test the relevance of their results for standardization, will be launched.
- The development of a Code of Practice for researchers on standardization will be initiated to strengthen the link between standardization and research/innovation through the European Research Area (ERA), by mid-2022.







Enable the next generation of standardization experts

 Standards rely on the best experts and Europe is facing a generation shift. The Commission will promote more academic awareness of standards through the future organization of EU University Days and the training of researchers.





The 2022 annual EU work program for European Standardization related to Life Science

Standardization urgencies set by the Communication on the EU standardization strategy:

- COVID-19 Vaccines and medicines production
- Medical devices & in vitro diagnostic medical devices
- Safe and trustworthy artificial intelligence systems



Why is standardization important for business and the life science industry?

Michael Bremerskov Jensen Functional Manager International Trade Danish Chamber of Commerce



Questions and debate



The importance of standardization for future use of diagnostics and personalized medicine

Ulf Bech Christensen Founder and CEO PentaBase



Introduction to PentaBase



Background

- PentaBase is a Danish, science-driven company built on unique DNA technologies, creating innovative workflows and PCR analyses
- We are enabling personalized treatment using sensitive, specific and robust monitoring of genetic biomarkers

Focus

- Leading provider of COVID-19 PCR in DK
- 80+ assays for somatic mutations in cancers
- Novel workflows for MSI and epigentic
- Unique oligonucleotide technologies



Company information

- Founded in 2006
- Head office in Odense, Denmark
- 7 laboratories in DK and 120+ employees



Introduction to PentaBase



Mission

 As a science-driven company with a unique DNA platform, PentaBase will provide customers with robust and precise genetic analyses and services.



Vision

- Every patient is unique and deserves to be individually treated.
- Our vision is to create a healthier society by personalised detection, prevention and treatment of diseases based on precise and timely genetic diagnostics.



Values

- Accountability
- Adaptive
- Caring
- Scientific excellence






Inventers of Intercalating Nucleic Acid - INA®

INA® oligo nucleotides have higher sensitivity, specificity and affinity towards their natural DNA targets

INA® is the only DNA platform technology that work by increasing the stacking effect




Personalized medicine





Last day of the old EU standard



Standards should be for the benifit of the patient



Scientist-to-Scientist

NGS data - Scientific exploration

Doctor-to-doctor

Patient data - changing hospitals General practitioner to hospitals and municipalities

Patient-to-X

My data to second opinion My data to private alternative My data to own research

Standards should be minimum promises to patients on issues that matters for the patient

Standards should not be seen as instruments to reduce competition nor innovation



Importance of diagnostics

The right diagnosis at the right time is the most important factor to ensure the foundation for the best possible treatment.







You can't prepare every detail, but prepare how to act on every detail


PentaBase wants to replace cancer packages with person promises




A case study

Colorectal cancer case study using SensiScreen® BRAF Liquid






Monitoring of BRAF V600E in Liquid Biopsies



- Chemotherapy
- Targeted therapy

^{*} Determined by SensiScreen® Liquid assay reference in approx. 200 µl plasma


Monitoring of BRAF V600E in Liquid Biopsies



- Chemotherapy
- Targeted therapy

^{*} Determined by SensiScreen® Liquid assay reference in approx. 200 µl plasma


Monitoring of BRAF V600E in Liquid Biopsies



- Chemotherapy
- Targeted therapy

^{*} Determined by SensiScreen® Liquid assay reference in approx. 200 µl plasma

Monitoring of BRAF V600E in Liquid Biopsies



Standards are called for when quality is low – but exceptions are available for some

Corona learnings

- Governments did set their own substandard performance rules
- The standards changed constantly influenced by politics
- Rather stick to a bad standard than admit mistakes

IVDR - New improved standard from tomorrow

- Hospitals are exempted from following the same rules
- Class D products must be validated by reference lab there are zero



Summary



Patients should be in focus when making standards



Standards should support improvements and innovation



Standards should be based on science



Standards should be easily understandable and apply for all



Let's create the basis for lovable standards





The standardization dilemma Sometimes the highest standard is to treat people differently

PentaBase

- Setting new standards in diagnostics



Short break



Standardization and innovation are prerequisites for each other

Martin Vesterby
MD Ph.d. of Health Tech Adopter Partner
Health Tech Hub Copenhagen



Standardization and innovation are prerequisites for each other

Or?



MAKING HEALTH TECH EVERYONE'S BUSINESS





Launch pad

For start-ups

Sustainable scaling in the Danish and global markets.

For large organizations

Launch and facilitation of internal innovation teams. Access to the global Health Tech ecosystem.

Catalyzer

Breaking silos

The entire system and every stakeholder in one place.

Global ecosysten access

Partnerships with global hubs enhance international mobility and start-up support.

<u>5</u>

Landing pad

Access to the Danish healthcare stakeholders through the hub and support on entry into Denmark as portal to the Nordic healthcare market.



CORE PARTNERS

:NDUSTRIENS FOND



netcompany





HEALTHCARE PARTNERS







INTERNATIONAL PARTNERS

HEALTH TECH NORDIC.









ECOSYSTEM PARTNERS









TECH PARTNERS













MEET OUR PEOPLE



Jesper Grønbæk CEO & Founder

- Team responsible
- Strategy & reporting
- Stakeholder management & lobbyist
- Fund investigation



Valentin Bejan CIO & Co-Founder



· International activities (startups, other hubs, internationalisation)



Martin Vesterby, Ph.D Health Tech adoption partner

- Adoption and collaborations
- Scaling of adopted solutions
- · 'Account' management



Line Rasmussen **Project coordinator**



- Day-to-day tasks in the Hub



Anett Falussy Head of Comms & **Events**



Golda Fania Community manager

- Project coordination

- Communications
- Global & ecosystem events
- Partner events



· Community engagement

- Internal events
- Social



Felix Frahm **Business analyst**

- Business tools
- Analysis
- Internationalisation



Cecilia Price Student assistant




Jannik Zeuthen Partner Development Manager


- Business tools
- Mentor network
- Internationalisation

- · Driving activities with partners · Recruitment of partners
- · Adding value to our members












\$257 billion

when adjusted for inflation to 2020 dollars







Standards

might have a oranding issue? nthe world of epreneurship






*Assumption is the mother of all f***ups

dardization ovation



Agile development came as a counter-reaction to the sequential development process called "The Waterfall Model" developed by Winston Royce in the 70s.





A Cry for more Creativity

"The worlds private and public sector leaders believe that rapid escalation of complexity is the biggest challenge confronting them. They expect it to continue, indeed to accelerate in the coming years."

Capitalizing on Complexity, IBM 2010



The definition of Agile Development:

-a set of principles for development under which requirements and solutions evolve through the collaborative effort of <u>self-organizing cross-functional teams</u>. It advocates adaptive planning, evolutionary development, early delivery, and continuous improvement, and it encourages rapid and flexible response to change.

These principles support the definition and continuing evolution of many development methods.



Manifesto for Agile Software Development:

- Individuals and interactions over processes and tools
- 2. Working solution over comprehensive documentation
- 3. Customer collaboration over contract negotiation
- 4. Responding to change over following a plan



The Pretotyping Manifesto

Innovators beat ideas
Pretotypes beat product-types
Building beat talking
Simplicity beats features
Now beats later
Commitment beats committees
Data beats opinions

Don't finish what you've started
Failure is an option
Scarcity bring clarity
The more the messier
Reinvent the wheel
Play with fire




Working solution over comprehensive documentation

The more the messier

Failure is an option







Formal definition of a standard

<u>Document</u> that provides, for common and repeated use, <u>rules</u>, <u>guidelines</u> or characteristics for activities or their results. The document is established by consensus and approved by a <u>recognized body</u>. The aim is the achievement of the optimal degree of <u>order</u> in a given context









INNOVATION
WITHOUT
CHANGE IS JUST
RESEARCH






The "Iron Triangle" in healthcare



Top 10 countries with most patents in biotechnology

Ranked by patents per million inhabitants, 2021




Source: Copenhagen Capacity on basis of fDi Benchmark, Financial Times Limited 2021

"The excellent outcomes in science insufficiently translate into commercial innovation, in particular in SMEs, start-ups and scale ups."

Peer Review of Denmark's R&I System 2020

Figure 16: Sales of new-to-market and new-to-firm innovations as a percentage of turnover, 2018



Source: European Commission- European Innovation Scoreboard 2019


Note: Indicator is calculated as sum of total turnover of new or significantly improved products, either newto-the-firm or new-to-the-market, for all enterprises.

"Sales of products from new-to-market and new-tofirm innovations are significantly lower, as a share of total revenue, than the EU average and most of the peer economies."





The "Iron Triangle" in healthcare








To achieve CHANGE at scale We need ADOPTION



Successful implementation of telemedicine depends on personal relations between company representatives and healthcare providers: A qualitative study of business models for Danish home telemonitoring









THANK YOU


Martin Vesterby

HEALTH TECH HUB COPENHAGEN



From research to practice to standardization

Serkawt Khola Ph.d., CEO and Founder Evoplexus Medics



EVOPLEXUS MEDICS

Serkawt Khola, PhD CEO & FOUNDER

s. khola@evoplexusmedics.com +45 4277 2851



- Our advanced solutions:
 - Support both clinicians and patients to better manage complex conditions
 - Improve quality of care to more patients
 - · Optimize resources and time
 - More precise treatments for individual patients



- Our journey
- The wild west!
- Cases:
 - Academic Research Al
 - First Patient: MS (Asperger, Dyslexia)
 - ESRD
 - Heart Failure
 - VAD and CKD
 - NawaQlinik for Precision Medicine
 - Current Collaborations and Representatives

Our Journey: T - 20X Years

Autonomous

Vehicles

Dawn of **Academic** Al Resarch (T-20X Years), ca.1998

First Medical Device Project: Fingertip Pulse Oxymeter with AI/PR – the 'Science Fiction'!

AI for MS Patient - 21

Al for: Dyslexia, Asperger, The Time-Data-**Space Machine** Learning Algorithm **Optimisation** Problem

Expression Biomarkers

JPL: The Space **Project**

Gene

EvoPlexus Al (R&D) Al for Healthcare market less ready (T-10X Years)

Projects: Heart Failure, NEC, AAA, ESRD, (COPD) **EvoPlexus**

Medics ApS (Sep 2019 -)



T = 2022

Precision **Healthcare:** VAD, CKD, PD (Multiple **Providers and Countries**)



The Evolution

Standards: -TC215

- DS273





The Research ... The Wild West (almost!)... The Standards and Guidelines.

T-20X Ys: Academic Research

- > Labs
- > Fragmented
- > Collaborations
- > Standards and Guidelines: Too few, or lack of, or unapplied etc.
- ➤ AI Too Early!



- First Patient MS (21 years ago):
 - Multiple Sclerosis (disease of the central nervous system)
 - Rapidly disabling
- Asperger and Dyslexia:
 - Data
 - Analytics

Standards and Guidelines:

➤ Use of AI - Too Early!



- ESRD:
 - Multi-provider, Multi-centre project
 - Concesus on methods, practices and rules
 - Data

Standards and Guidelines:

- > Data: identification, coding, collection, storage, sharing
- Privacy, Security, Safety
- > Interpretations, Interoperations, Integrations
- > AI definitions, methods, algorithms, presentations, interpretations



- Heart Failure:
 - Single centre project
 - Multi-target stakeholders
 - Unseen methods
 - Data: collection, merging, values, types etc.

Standards and Guidelines:

- > Smoother processes
- > Better Outcomes
- > AI Concensus on definitions, methods, algorithms, presentations, interpretations lesser problem!



- VAD and CKD:
 - Main partner, but multiple providers/collaborations
 - Multiple countries
 - Highly varying data sources, collection methods, storage, consent, sharing, timelines etc.

Standards and Guidelines:

- ➤ Help streamline processes
- > Common grounds, common understandings
- ➤ AI Difficulties!



Patient Interrogation











NawaQlinik

AI-Enabled Platform for Complete Patient Pathway




An AI-Enabled smartphone application for users/patients

Track Vascular Access Conditions



9 of 9

OUR CURRENT COLLABORATIONS AND REPRESENTATIVES



INVESTORS - PARTNERSHIPS - COLLABORATIONS Please contact us:

info@evoplexusmedics.com

hr@evoplexusmedics.com

THANK YOU WE LOOK FORWARD TO HEARING FROM YOU



Why innovation and investment in evidence-based standards are crucial for trade in the future

Gitte Petersen CEO and co-founder Genomic Expression



Dansk Standard: 2022/05/24

By Gitte Pedersen, CEO and co-founder and member of ESIR2

Mission: to save lives and make healthcare more effective

Vision: By analyzing RNA we can monitor health, detect disease and design next generation cures

Who pays for healthcare?





YOU

U.S. health care spending grew 9.7 percent in 2020, reaching \$4.1 trillion or \$12,530 per person/year Europe, the average cost of international health insurance in 2018 is spread out between USD 8,786 in the UK and USD 6,585 in Romania, Croatia, and Slovakia.




Health is Dynamic and not binary


COVID-19 has transforming delivery of health care



Yesterday: Pre COVID-19 it could take weeks to a month from onset of a symptom to entering into treatment



Today: We detect disease prior to manifestation of symptoms in 24 hrs








85% of older adults have at least one chronic health condition, and 60% have at least two chronic conditions

Most chronic conditions are life style related and can be reversed with non-pharmaceutical Intervention





People living with diseases in the USA

Mental 70M

Bi-polar: Borna disease virus, Borrelia species bacteria. Impairment, herpes simplex virus

ADHD: Bacteria borrelia burgdorferi and streptococcus, and with HIV and enterovirus. Viral infections during pregnancy, at birth, and in early childhood are risk factors

Autism: rubella virus or cytomegalovirus and Clostridia bacterial

Anxiety: cytomegalovirus, Epstein-Barr virus, bacterium helicobacter pylori.

> Dementia: herpes simplex virus, cytomegalovirus, West Nile virus, Borna disease virus, and HIV. Borrelia species bacteria.

> > **Depression:** Cytomegalovirus, West Nile virus, Epstein-Barr virus, Borna disease virus, as bartonella and borrelia species bacteria.

Auto **I**mmune 23M

Enteroviruses, Epstein-Barr virus, cytomegalovirus, parvovirus B19, HIV,

5.7M bacterium mycobacterium Herpes simplex virus tuberculosis gingivalis, chlamydia pneumoniae helicobacter pylori and helicobacter pylori

Alzheimer

Cancer 16M

20-30% of cancers are caused by Infectious agents and 30% due to life style (smoking, drinking obesity)

50M


Respiratory

35M or 10% of US population has Asthma: associated with rhinovirus, human respiratory syncytial virus, and the bacterium chlamydia pneumoniae. 17M or 5% COPD, emphysema, chronic bronchitis

Genomic OCESSION

108M or 31% of US population is **Obese**: associated with adenovirus 36, which is found in 30% of obese people, but only in 11% of non-obese people

Through these types of approaches, we have identified a number of factors that impact tumor growth and response to cancer treatment that may be targeted




Vitamin D Benefits

- 1. Promotes Immune Health
- 2. Promotes Bone Health
- 3. Promotes Dental Health
- 4. Promotes Tissue Health
- 5. Supports Colon Health

Stakeholder analysis

Only industry where the ultimately beneficiary is not the decision maker nor the payor








Dependent stakeholders: urgent and legitimate but little



Power





Dominant stakeholders, power and legitimacy, no urgency



Definitive stakeholders: power, legitimacy and urgency (KOL)

Demanding stakeholders, urgency but no power

"In the future, most healthcare decisions will be based on collectively-derived insights that are synthesized in real-time and delivered at the point of care."


Chris Klomp, CEO Collective Medical

Collective medical



As a result of the digitization and increasing liquidity of healthcare data, today, we're seeing record amounts of innovation and investment in the industry from a variety of participants, such as startups and large tech companies, as well as big-box retailers and traditional healthcare organizations.










Exponentially scalable platform for Next Generation Cures



OneRNA® could save lives NOW




We identify 5 already approved drugs in 100% off the patients

Paradigm shift from static standard of care model to dynamic truly Individualized treatment
















From RNA code to drug 12 month





Important standards moving into health 2.0



- 1) Protection of consumer health data e.g. GPDR, HIPAA etc
- 2) Standardization of consent to use data and biological information
- 3) Standardization of regulatory procedures US<>EU
- 4) Standardization of disease definitions and codes
- 5)Standardization of data structure and programs for EMR (HL7)
- 6) Definition of health as the absence of detected disease

HL7



HL7 standards are healthcare-specific formatted messages that support a variety of system integrations and interoperability—and enable EHRs to communicate with a variety of systems that operate outside the EHR

HL7 Vision

A world in which everyone can securely access and use the right health data when and where they need it.

HL7 Mission

To provide standards that empower global health data interoperability.

Google sued for using the NHS data of 1.6 million Britons 'without their knowledge or consent'



The Royal Free NHS Trust in London, which gave Google the patient data, was previously told the move was illegal following an investigation by the Information Commissioner's Office.



(1) Monday 16 May 2022 13:45, UK



Conclusions



I)Our healthcare system have dramatically changed during COVID19 -> we learned that we can deliver care using the internet Telehealth and diagnostics

2)We can leverage this change to continue improving on delivering of care using Telehealth and accurate

diagnostics

3) The consumer is the key stakeholder and willing (in the USA) to spend \$1.5/pa on wellness

4) Healthcare systems need to spend more \$\$ in monitoring health to reduce cost of care

5)People and patients have to be involved and sharing of data is necessary to achieve the improvements that data technology provides and develop next generation drugs




Panel debate and questions



Conclusion and next step

Jeanett Fleron Senior Consultant, Danish Standards





Why participate?

- Gain influence on the national strategic direction for standardization
- Gain influence on the framework and on the requirements of the future standards within the life science field
- National and global network
- Knowledge of e.g. future requirements, trends and new research & development
- Get inspiration to innovation and new partnerships
- Strengthen Denmark's and the Danish society's position in this field





Examples of national committees


- Health Informatics (S-273 Sundhedsinformatik)
- Biotechnology (S-809 Bioteknologi)
- Quality management and corresponding general aspect for medical devices (S-257 Medicinsk udstyr – ledelse og kvalitet)
- New DS Task Force for life science & standardization!





Next step

- The presentations and recording from the webinar will be made available at Danish Standards' webpage (ds.dk)
- Contact Danish Standards for general information
- Contact Danish Standards (Jeanett Fleron) if you wish to participate in the work or learn more about the ongoing standardization work



Contact





Jeanett Fleron Senior Consultant

E: jef@ds.dk T: 39 96 61 72